Vanda Pharmaceuticals, Inc. (VNDA) Misses Q1 EPS by 49c
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $6.26 +0.81%
EPS Growth %: -30.4%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
CRMT, PKE, More
EPS Growth %: -30.4%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q1 EPS of ($0.79), $0.49 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.75 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
- Morgan Stanley Resumes American Eagle Outfitters (AEO) at Equalweight
- Incyte acquires Vega Therapeutics for $1.25B upfront
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
